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Abstract: Polylactide (PLA) electrospun microfibers were prepared and loaded with triclosan (TCS), ketoprofen
(KTP), or their combination to obtain multifunctional scaffolds with bactericide and anti-inflammatory properties.
Continuous and porous fibers with diameters in the micrometer scale and a unimodal distribution were successfully
attained using a dual-electrospinning technique. Dual drug-loaded scaffolds showed a peculiar release that was in
contrast to the single drug-loaded systems, which suggested the establishment of intermolecular interactions that
delayed TCS and KTP release. Antimicrobial activity of all TCS-loaded electrospun scaffolds was demonstrated
against E. coli and M. luteus bacteria; and furthermore, KTP-loaded samples slightly showed bactericide activity. Bio-
compatibility of scaffolds was evaluated by adhesion and proliferation assays, and interestingly, the dual drug-load
systems were able to support high TCS doses without adverse effects.
Keywords: biomaterials, electrospinning, dual drug-release, polylactide, bactericide, triclosan, ketoprofen.
Introduction
Polylactide (PLA) is currently one of most attractive bio-
degradable polymers because it is derived from renewable
resources, can be easily processed and has many applications
ranging from commodity to specialty uses.1-5 PLA is gaining
special attention in the biomedical field. Specifically, devices
including degradable sutures, drug releasing micro/nanopar-
ticles, and porous scaffolds for cellular applications can be
mentioned.6-10 The great advantages of PLA are due in part
to its ability to degrade into the naturally occurring metabolite
lactic acid under physiological conditions, but other exceptional
qualities, like biocompatibility, FDA approval for clinical use,
low immunogenicity and good mechanical properties must
also be considered.
PLA can be obtained by ring opening polymerization of
L-lactide and/or D-lactide, a process that allows obtaining a
large number of stereo-copolymers by changing their L/D
ratio. Properties of PLA are strongly dependent on its optical
purity; for example, PLA can range from semicrystalline to
completely amorphous.11 The degree of crystallinity and even
molecular orientation also has a strong influence on PLA
biodegradability; specifically, the selection of adequate pro-
cessing conditions is important to achieve a specific orientation
for a given stereoregularity. For example, Lee et al. concluded
that molecular orientation in amorphous PLA increased with
decreasing stretching temperature whereas semicrystalline
samples required increasing temperatures.12 It seems that,
for amorphous samples, the most important effect concerns
the highest possible orientation when molecular relaxation
is hindered by a temperature decrease. For semicrystalline
samples, the orientation phenomenon involves the deformation
of formed spherulites, and consequently higher temperatures
are needed.
Electrospinning is currently one of the simplest methods
to draw nano and microfibers from a polymer solution. Basically,
the surface tension of a liquid droplet can be counteracted by the
electrostatic repulsion due to the charging of the body of the
liquid by a sufficiently high voltage. The droplet is stretched
and may form a liquid jet if its molecular cohesion is suffi-
ciently high.13 Scaffolds prepared by electrospinning showed
particularly good potential for drug delivery applications due
to their large surface area and interconnected pore struc-
ture.14,15 Moreover, drug release behavior can be easily con-
trolled by the morphology and composition of fibers.16,17
Drug-loaded electrospun scaffolds can also be easily fabricated
into various shapes (e.g. membranes or tubes) for different
applications, such as wound dressing and nerve conduits.18,19
To date, most studies of electrospun scaffolds for drug delivery
have been focused on sustained release of a single drug.
However, it is clear that the use of different drugs is a promising
strategy that allows combination therapy and may even induce
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synergic effects. Studies on dual drug-loaded systems, mainly
fibers fabricated by coaxial electrospinning20 and multilayered
electrospun polymer mats,21 demonstrated different release
kinetics from simple systems and/or that the severe initial
burst release could be retarded or even negated.
One of the main applications for electrospun scaffolds is
its potential use as a matrix for wound healing. The success in
wound healing can be handled by the control of various events,
such as accelerating tissue regeneration (e.g. by promoting
cell proliferation), preventing rejection of the implanted material
(e.g. by improving cell adhesion on the material or by locally
suppressing the immune response), or reducing the risk of
adverse effects associated with tissue damage (e.g. by prevent-
ing infection by opportunistic microorganisms). Thus, the
release of two or more different drugs at the proper time and
in appropriate doses may be required during treatment of
wound healing. For example, post-surgical infection is a com-
mon problem after surgical procedures. This requires the release
of some drugs, including antibiotics, from the drug-loaded
biomaterial in a sustained manner to prevent infections over
a short or long period. The rapid release of anti-inflammatory
agents and analgesics is also necessary to reduce the cellular
immune response and patient’s pain, respectively. Thus, it is
highly desirable and challenging to develop novel drug deliv-
ery carriers that can control the release of multiple drugs with
different release kinetics.
In the present study, the feasibility of loading active agents of
different nature and with diverse therapeutic effects into
polylactide fibers is assessed with the aim of developing
multifunctional electrospun materials for regenerative med-
icine applications. A system involving two drugs, triclosan
(TCS) as the antibacterial agent and ketoprofen (KTP) as a
conventional anti-inflammatory drug, was considered. Figure 1
shows the chemical structure of compounds used. Modula-
tion of the therapeutic effect is expected to occur because of
the difference in release of these drugs from scaffolds con-
stituted by electrospun fibers. The influence of polymer matrix
crystallinity on the release behavior is also determined. To
this end, electrospun scaffolds were prepared using PLAs having
slightly different ratios between L- and D-lactide units.
Experimental
Materials. Two commercial PLA grades from Natureworks®
with 95.8 and 98 wt% L-lactic isomer content were used,
i.e. PLA 2002D and PLA 4032D, respectively. According
to the manufacturer, PLA 2002D is a transparent solid with
a density of 1.24 g·cc-1. Its calorimetric and mechanical proper-
ties are defined by a glass transition temperature (Tg) of
58 ºC, a melting point (Tm) of 153 ºC, a tensile modulus (E)
of 3,500 MPa, a tensile strength () of 53-60 MPa and a tensile
elongation () of 6%. PLA 4032D has a translucent appear-
ance, a density of 1.24 g·cc-1 and very different properties
from the sample with higher D-lactide content. Thus, Tg, Tm,
E, , and  values were reported to be 70 ºC, 160 ºC, 3,440-
3,784 MPa, 103.2-144.5 MPa, and 100-180%, respectively.
Molecular weights determined by GPC were quite similar;
specifically Mn, Mw, and polydispersity index were 98,100
g·mol-1, 181,000 g·mol-1, and 1.85 for PLA 2002D and 84,200
g·mol-1, 179,400 g·mol-1, and 2.13 for PLA 4032D.22,23
Trichloromethane (Chloroform), acetone, dimethylsulfoxide
(DMSO), triclosan or irgasan (TCS), ketoprofen (KTP) and
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bro-
mide (MTT) were purchased from Sigma-Aldrich (St. Louis,
USA).
Vero (kidney epithelial cells extracted from African green
monkey) and MDCK (kidney epithelial cells derived from
Madin-Darby Canine) were purchased from ATCC (USA).
Escherichia coli CECT 101 and Micrococcus luteus CECT
245 bacteria strains were obtained from the Spanish Collec-
tion of Type Culture (Valencia, Spain).
Drug-Loaded PLA Electrospun Microfibers. Scaffolds
constituted by PLA 2002D and PLA 4032D microfibers were
prepared by electrospinning, which also allowed loading the
two selected drugs (i.e., TCS and KTP). The procedure con-
sisted in dissolving the PLA in a chloroform-acetone mixture
(2:1 v/v). For drug-loaded samples, 1 mL of dimethysulfoxide
(DMSO) containing the corresponding drug was subsequently
added and the mixture was vortexed to obtain an electro-
spinable solution. Final PLA concentration was 10% (w/v)
whereas for drug-loaded samples KTP and TCS concentra-
tions were 1% (w/v) and 3% (w/v), respectively. A plastic
syringe of 5 mL (Becton Dickson, Spain) was filled with the
corresponding solution and electrospinning was carried out
between the tip of a 18G needle (Terumo, Belgium) connected
to the anode and the static collector connected to the cathode.
Figure 1. Chemical structures of polylactide (D,L-PLA), triclosan
(TCS), and ketoprofen (KTP).
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The DC voltage was applied using a high voltage supply
(ES30-5W model, Gamma High Voltage Research, USA). The
flow rate was controlled using a KD100 infusion syringe pump
(KD Scientific Inc., USA). The polymer jet was collected on
an aluminum foil and 14 mm diameter coverslips to evaluate
cell adhesion and proliferation. All electrospinning proce-
dures were conducted at room temperature.
Morphology and Crystallinity of Dual Drug-Loaded
PLA Microfibers. The diameter measurements and inspection
of fiber textures were performed by scanning electron micros-
copy (SEM) using a Focus Ion Beam Zeiss Neon 40 instrument
(Carl Zeiss, Germany). Carbon coating was accomplished
with a Mitec K950 Sputter Coater (fitted with a film thickness
monitor k150x). Samples were viewed at an accelerating voltage
of 5 kV.
Calorimetric data were obtained by differential scanning
calorimetry (DSC) with a TA Instruments Q100 series equipped
with a refrigeration cooling system (RCS). Experiments were
conducted under a flow of dry nitrogen with a sample weight
of approximately 5 mg and calibration was performed with
indium. Heating and cooling runs were carried out at a rate
of 20 ºC·min-1 and 10 ºC·min-1, respectively.
Fourier transform infrared (FTIR) spectra were recorded on
a FTIR 4100 Jasco spectrophotometer. The samples were placed
in an attenuated total reflectance accessory with thermal control
and a diamond crystal (Specac MKII Golden Gate Heated
Single Reflection Diamond ATR).
Release Experiments. Controlled release experiments were
performed with electrospun scaffolds cut into small square
pieces (20×20×0.1 mm3). The samples were weighed and placed
into polypropylene tubes. Two release media with different
hydrophobicity and solvent ability were used: a typical phos-
phate buffer saline or (PBS) and PBS supplemented with 70%
(v/v) of ethanol. The second one was less hydrophilic than
PBS and was interesting for simulating the supplement of serum
in the medium.24 Drug release was carried out in 50 mL of
the release medium at 25 ºC for 1 week. Drug concentration
in the release medium was evaluated by UV-Vis spectroscopy
using a UV-3600 spectrophotometer (Shimadzu, Japan). Calibra-
tion curves were obtained by plotting the absorbance measured
at the corresponding wavelengths against drug concentration.
Samples (1 mL) were drawn from the release medium at
predetermined intervals and an equal volume of fresh medium
was added to the release vessel. All drug release tests were
carried out using three replicates to control the homogeneity
of the release, and the results obtained were averaged.
Antimicrobial Test: Bacterial Growth and Adhesion
Assays. Escherichia coli (E. coli) and Micrococcus luteus (M.
luteus) bacteria were selected to evaluate the antimicrobial
effect of TCS and KTP loaded electrospun scaffolds. The bacte-
ria were previously grown aerobically to exponential phase
in broth culture (5 g·L-1 beef extract, 5 g·L-1 NaCl, 10 g·L-1
peptone, pH 7.2).
Growth experiments were performed in tubes of 15 mL.
103 CFU (colony forming units) were seeded in 5 mL of broth
culture in the presence of the electrospun scaffolds. The cul-
tures were incubated at 37 ºC and agitated at 80 rpm. After
incubation for 24 and 48 h, an aliquot of 100 µL was diluted
10 times with distilled water and the absorbance at 600 nm
was measured. The bacterial number was determined using
a McFarland curve scale and graphically represented as rel-
ative percentages of the control.
Adhesion experiments were carried out by seeding 107-108
CFU in 5 mL of broth culture in the presence of the electro-
spun scaffolds. The cultures were incubated at 37 ºC and agi-
tated at 80 rpm. After incubation, the cultures were aspired
and the material washed once with distilled water. Then, 1 mL
of sterile 0.01 M sodium thiosulfate was added and the mix-
ture was vortexed for 2 min and left to repose for 30 min in
order to remove the bacteria. Finally, 4 mL of broth culture
was added and the tubes were incubated at 37 ºC for 24 h and
agitated at 80 rpm. The bacterial number was determined as
above indicated.
All assays were performed in triplicate and the results
averaged. Analysis of variance (ANOVA) followed by Tukey
test were conducted as statistical analyses at a confidence
level of 95% (p<0.05). Additionally, correlation coefficients
(r) were calculated to evaluate the relation between antibac-
terial effect and drug release.
In vitro Biocompatibility Assays: Cell Adhesion and
Proliferation. MDCK and Vero cells were cultured in Dul-
becco’s Modified Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum, 1% penicillin/streptomycin
and 2 mM L-glutamine at 37 ºC in a humidified atmosphere
with 5% CO2 and 95% air. The culture medium was changed
every two days and, for sub-culture, cell monolayers were rinsed
with phosphate buffered saline (PBS) and detached by incu-
bation with trypsin-ethylenediaminetetraacetic acid (EDTA)
(0.25%) at 37 ºC for 2-5 min. Cell concentration was deter-
mined by counting with a Neubauer chamber using 4% try-
pan-blue as dye vital. Detached cells with viability 95%
were used for biocompatibility assays.
The unloaded and antioxidant loaded PLA electrospun
microfibers were cut into square pieces (10×10×0.1 mm3).
These samples were placed into the wells of a multi-well
culture plate and sterilized by UV-radiation in a laminar flux
cabinet for 15 min. To fix the samples in the well, a small drop
of silicone (Silbione® MED ADH 4300 RTV, Bluestar Silicones
France SAS, Lyon, France) was used as the adhesive. Samples
were incubated in 1 mL of the culture medium under culture
conditions for 30 min to equilibrate the material. Finally, the
medium was aspired and the material was evaluated for cell
adhesion and proliferation by exposing cells to direct con-
tact with the material surface.
To assess cell adhesion, aliquots of 50-100 µL containing
5×104 cells were seeded onto the electrospun scaffolds in
the wells. The plate was incubated in culture conditions for
30 min to allow cell attachment to the material surface. Then,
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1 mL of the culture medium was added to each well and the
plate was incubated for 24 h. Finally, cell viability was deter-
mined by the MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphen-
yltetrazolium bromide) assay. Controls were performed by
cell culture on the polystyrene surface of the plate (TCPS).
Cell proliferation was evaluated by a similar procedure to
the adhesion assay, but the aliquot of 50-100 µL contained
2×104 cells. The cultures were maintained for 7 days to allow
cell growth and adequate cell confluence in the well. The
medium was renewed every two days. Finally, cell viability
was determined by the MTT assay.
Each sample was evaluated using five replicates and the
results were averaged and graphically represented. The statistical
analysis was performed by one-way ANOVA to compare the
means of all groups; Tukey test was then applied to deter-
mine a statistically significant difference between two studied
groups. The tests were performed with a confidence level of
95% (p<0.05).
Results and Discussion
Morphology of Dual Drug-Loaded PLA Microfibers.
Morphology of electrospun fibers depends on both solution
properties (e.g. viscosity, surface tension, dielectric constant,
volatility and concentration) and operational parameters
(e.g. strength of the applied electrical field, tip-collector dis-
tance and flow rate).25-27 Selection of an appropriate solvent
system is one of the most crucial points, especially in elec-
trospinning of compounds with highly different characteris-
tics (e.g. polymer and drugs). It should be pointed out that
physicochemical properties of the solution can be affected by
the incorporation of active drugs and that the system must
be accurately chosen to support the load of one or both drugs
and render appropriate electrospun fibers.28 
It was reported that the selection of solvent was also cru-
cial to control the diameter of PLA electrospun fibers. Thus,
diameters could be easily varied from 100 nm (i.e., nanome-
ter scale) to 2 m (i.e., micrometer scale) by using dimethyl
formamide and chloroform-acetone (2:1 v/v) mixture as sol-
vents, respectively, when polymer concentration was kept at
10% (w/v).29,30 Nevertheless, PLA concentration also played
a determinant role because nanofibers could again be obtained
when it was lower than 5% (w/v).31
The above conclusions were taken into account in this
study since a micrometer scale was preferred to detect release
differences between drugs and from distinct PLA matrices.
The main problem was to choose a solvent based on the chloro-
form-acetone mixture able to dissolve 10% (w/v) of PLA and
the two selected drugs with solubility characteristics differ-
ent from those of PLA. Note the large difference between
Hildebrand parameters reported for PLA32 (i.e., 9.87 (cal·cm-3)0.5)
and TCS33 (i.e., 14.38 (cal·cm-3)0.5). Finally, drugs were dis-
solved in dimethyl sulfoxide and subsequently added to the
former PLA solution to obtain a tricomponent solvent mixture
(chloroform:acetone:DMSO 6:3:1 v/v/v) compatible with the
selected concentrations of PLA (10% (w/v)), TCS (3% (w/v))
and KTP (1% (w/v)).
Figure 2 shows the SEM images of the fiber matrices and
the corresponding diameter distribution analysis of electro-
spun fibers prepared under previously optimized operational
parameters (i.e., applied voltage, flow rate and tip-collector
distance of 15 kV, 10 mL·h-1 and 12.5 cm, respectively). A
unimodal Gaussian diameter distribution was always deter-
mined (Figure 2, insets).
Average diameters determined for all samples are summa-
rized in Table I. The success of the electrospinning proce-
dure to obtain fibers in the micrometer scale is confirmed in all
cases. Differences between unloaded fibers prepared from the
two PLA grades were not highly significant (average value
of 1.76 m). However, the incorporation of the drug always led
to a diameter increase following the order TCS/KTP <TCS
< KTP, with average diameters being 1.98, 2.82, and 3.33 m,
respectively. Probably, the physicochemical characteristics
of the electrospun solutions were more influenced by the incor-
poration of bigger KTP molecules (Figure 1). These caused
the largest increase on the fiber diameter despite the drug
load percentage was the smallest. It should also be pointed out
that TCS and KTP drugs caused a significant discrepancy
between fiber diameters of samples coming from the two
PLA grades, with a higher increase being detected for PLA
4032D samples. These changes may reflect a different
degree of molecular orientation and even different compact-
ness of the amorphous phases between the two electrospun
polymers. Finally, when the drugs, TCS and KTP, were loaded
simultaneously in both PLA samples, diameter values were
only slightly higher than those obtained for unloaded fibers
(e.g. 1.77 µm with respect to 1.66 µm for the PLA 4032D,
and 2.19 µm regarding 1.86 for the PLA 2002D samples).
This feature suggests some kind of interaction between TCS
and KTP (e.g. hydrogen bonds between hydroxyl and carbonyl
groups or stacking between aromatic groups) that could also
be favored by the higher total drug content with respect to
the single drug-loaded systems.
Figure 3 shows high-magnification SEM images of the
different fibers which reveal a very similar porous texture for
all cases. 
Incorporation of Drugs into Electrospun Microfibers.
FTIR spectra of unloaded and drug-loaded PLA 2002D sam-
ples in Figure 4 illustrate two interesting points. First, no
significant differences exist between typical PLA absorption
bands of scaffolds prepared from the two PLA grades or
scaffolds loaded with the drugs or their combination. The given
spectral region is sensitive to molecular conformation; con-
sequently, it can be concluded that differences between electro-
spun samples were not large enough to be detected by FTIR.
As will be discussed later, although the amorphous content
may change slightly with the PLA grade and drug load, it seems
that polymer chains attained a similar molecular conforma-
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tion after the electrospinning process. In fact, processed PLA
microfibers were always practically amorphous but a high
degree of molecular orientation was induced during electro-
spinning.34 Note, for example, that all spectra have similar
intensity for the shoulder band at 1209 cm-1 (as (C-O-C) +
ras(CH3) for a 107 helical conformation) and the band at 1263
cm-1 ( (CH) + (C-O-C) for a random conformation). Also,
the relative proportion between bands at 1387 cm-1 (s (CH3),
amorphous form) and 1360 cm-1 ( (CH), semicrystalline form)
became practically invariable.35
Figure 2. SEM micrographs of unloaded (a,b), triclosan-loaded (c,d), ketoprofen-loaded (e,f) and dual drug-loaded (g,h) in PLA 2002D
(a,c,e,g) and PLA 4032D (b,d,f,h) electrospun microfibers.
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FTIR spectra were sufficiently sensitive to detect the incorpo-
rated drugs despite the relatively low loading percentages.
More precisely, TCS was clearly identified in the microfibers
through the characteristic peak at 1476 cm-1, attributed to
the C=C stretching vibration of benzene rings.36 However,
lesser loaded KTP (i.e., 1% (w/v) as opposed to 3% (w/v))
could be hardly detected through the strongest peak at 1652 cm-1,
attributed to the C=O stretching.37 Unfortunately, FTIR spectra
were not able to detect specific interactions in the dual drug-
loaded system due to the low intensity of the involved peaks.
Thermal Properties of Unloaded and Drug Loaded
PLA Electrospun Scaffolds. Table II summarizes the main
calorimetric data obtained from the heating run of unloaded
and drug-loaded scaffolds from the two PLA grades, whereas
the corresponding DSC traces are shown in Figure 5. Data
Table I. Diameters of Unloaded and Drug Loaded Electrospun
PLA Fibers
Sample Diametera,b (µm)
PLA 2002D 1.86 ± 0.06
PLA 4032D 1.66 ± 0.05
PLA 2002D + TCS 2.12 ± 0.01
PLA 4032D + TCS 3.53 ± 0.04
PLA 2002D + KTP 2.95 ± 0.02
PLA 4032D + KTP 3.72 ± 0.06
PLA 2002D + TCS/KTP 2.19 ± 0.01
PLA 4032D + TCS/KTP 1.77 ± 0.03
aFibers were obtained using the same electrospinning operational
parameters: applied voltage of 15 kV, flow rate of 10 mL/h and tip-
collector distance of 12.5 cm. bMean value ± standard deviation. 
Figure 3. High-magnification SEM micrographs showing the
surface texture of unloaded (a,b), triclosan-loaded (c,d), ketopro-
fen-loaded (e,f), and dual drug-loaded (g,h) PLA 2002D (a,c,e,g)
and PLA 4032D (b,d,f,h) electrospun microfibers. 
Figure 4. FTIR spectra (1800-1000 cm-1 region) of PLA 2002D,
PLA 4032D, PLA 2002D + TCS, PLA 2002D + KTP, and PLA
2002D + TCS/KTP scaffolds. 
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corresponding to the two PLA pellets are also given for compar-
ative purposes. It is clear that both samples were manufac-
tured in a semicrystalline form attained after annealing treatment.
Values clearly reflect the impact of a small increase in D-lactide
content (i.e., from 2% wt to 4.2% wt) on both amorphous
and crystalline phases, with remarkable changes in glass transi-
tion and melting temperatures, respectively. More interest-
ingly, the thermal characteristics of electrospun samples are
significantly different from the initial ones.
Both PLA 2002D and PLA 4032D electrospun samples
became practically amorphous (degree of crystallinity, Cc,
close to 0.07-0.08, as indicated in Table II). Note however
that cold crystallization peaks can be clearly observed during
the heating run of both samples and relatively high degrees
of crystallinity (i.e., 0.25 and 0.29) could be estimated from
the subsequent melting enthalpies. These values were close
to those deduced for the corresponding commercial pellet
samples and clearly higher than those obtained from the heating
run performed with commercial samples after being slowly
cooled from the melt state.29 This feature suggests that elec-
trospun PLA fibers can easily crystallize during a subsequent
heating run as a consequence of a remarkable degree of molecu-
lar orientation that could be attained in the electrospinning
process. The high relaxation peak observed for the PLA
4032D electrospun sample, which indicates the great ability
of this PLA grade to achieve the equilibrium thermodynamic
conditions characterized by higher stiffness and lower enthalpy
and volume, is also worth noting. In addition, this close to
equilibrium condition led to a fictive glass transition tem-
perature38 clearly lower than that observed in the initial sam-
ple of PLA 4032D (i.e., 62.4 ºC as opposed to 69.3 ºC) and
close to those detected for both PLA 2002D initial and elec-
trospun samples (59.6 ºC and 59.3 ºC). Cold crystallization
took place in a narrow temperature range for PLA 4032D,
whereas the use of PLA 2002D involved a wide temperature
range, suggesting greater difficulty for molecular rearrange-
ment.
Incorporation of drugs had effects on thermal properties
that depended on the polymer grade and the drug:
(a) Incorporation of TCS led to a significant decrease in
the melting temperature of the two PLA samples (i.e., close
to 13 ºC), suggesting partial incorporation into the crystalline
Figure 5. DSC heating runs (20 ºC·min-1) of unloaded (a) and drug-loaded (b) PLA 2002D and PLA 4032D electrospun scaffolds.
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structure. Both loaded samples were practically amorphous
after electrospinning but the cold crystallization process was
more favorable for the more regular PLA 4032D sample. Final
crystallinities were logically lower than those of unloaded
samples (i.e., 0.21 as opposed to 0.29 for PLA 4032D and 0.09
as opposed to 0.25 for PLA 2002D). TCS also had a plasticizing
effect, as suggested by the significant decrease in the glass
transition temperature. In addition, the trend to achieve the
compact arrangement characteristic of an equilibrium condition
was practically supressed for PLA 4032D derived scaffolds
since the enthalpy relaxation peak was hardly detected.
(b) The melting point decrease was less significant (i.e., close
to 6 ºC) for scaffolds containing KTP as consequence of
their lower drug load. In this case, the most significant feature
was the high crystallinity attained after the cold crystallization
process, which, in the case of PLA 4032D scaffolds, was even
greater than for the unloaded sample. It seems that KTP could
also act as a nucleating agent, as deduced from the decrease
of the cold crystallization temperature and even from the
narrower temperature range for the less crystalline PLA 2002D
scaffold. Glass transition temperatures and enthalpy relax-
ation peaks decreased too, suggesting again a plasticizing
effect of KTP and greater difficulty in obtaining the more
compact equilibrium arrangement. Nevertheless, this trend
was not completely supressed in the case of PLA 4032D. 
(c) The dual drug-loaded samples showed peculiar DSC traces,
which were the result of the effect caused by TCS and KTP.
Thus, the decrease in the melting and glass transition tem-
peratures was higher (12-17 ºC and 25-29 ºC, respectively),
enthalpy relaxation was completely suppressed and high crystal-
linity was attained before (for PLA 4032D sample) and after
cold crystallization (for both PLA grades) due to the KTP nucleat-
ing effect. The high crystallinity that could again be directly
attained in the electrospinning of the PLA 4032D grade in
the presence of KTP is worth noting. Finally, melting peaks
were, in this case, clearly complex due to the presence of crys-
tals with different degrees of perfection (incorporation of impuri-
ties or/and different lamellar thicknesses).
Drug Release from Scaffolds of PLA with Different D-
Lactide Content. A quantitative study was also attempted
to follow the release of KTP and TCS from the two different
PLA matrices. Release in the less hydrophilic medium con-
taining ethanol (PBS:EtOH 3:7 v/v) was monitored through
absorbance measurements at 270 and 281 nm for KTP and
TCS, respectively, whereas values were measured at 260 and
290 nm for KTP and TCS, respectively, when hydrophilic PBS
medium was employed. In all cases, concentrations were
evaluated using the molar absorption coefficient (ε) calculated
for each drug in the corresponding release medium. These values
were 7610 and 6908 M-1cm-1 for TCS in PBS: EtOH and PBS
media, respectively, and 23,604 and 22,487 M-1cm-1 for KTP
in phosphate buffered saline:ethanol (PBS:EtOH) and PBS
media, respectively.
Drug release plots in Figures 6 and 7 highlight differences
depending on the PLA grade and logically on the selected
medium. In all cases, the release attained a maximum value
that mainly depends not only on the drug equilibrium distri-
bution between microfibers and the release medium but also
on the ability of microfibers to trap the drug efficiently. Hence,
the final release percentage was always lower when the more
hydrophilic PBS medium was used, in agreement with the
hydrophobic character of the drugs and PLA. Furthermore,
PLA 2002D microfibers showed the highest release percent-
ages, probably as a consequence of the decrease in trapping
efficiency caused by their lower molecular orientation and
less dense molecular arrangement. Thus, for example, release
Table II. Calorimetric Data from the Heating Scan Performed with Drug Loaded and Unloads in the Electrospun Samples
Sample Tg (ºC) ΔCp (J/g ºC) Tc (ºC) ΔHcb (J/g) Tm c (ºC) ΔHmb (J/g) ΔHm - ΔHcb (J/g) cd
PLA 2002Da 59.6 0.57 - - 149.3 29.2 29.2 0.28
PLA 2002D 59.3 0.62 106.0 18.5 146.4 26.1 7.6 0.07, 0.25
PLA 4032Da 69.3 0.23 - - 167.0 35.0 35.0 0.33
PLA 4032D 62.4 0.55 100.2 22.6 165.9 30.8 8.2 0.08, 0.29
PLA 2002D +TCS 39.3 0.53 94.6 8.1 132.6 9.8 1.7 0.02, 0.09
PLA 4032D +TCS 40.1 0.50 89.1 22.3 153.9 22.6 0.3 < 0.01, 0.21
PLA 2002D + KTP 43.7 0.40 78.4 22.8 140.6 23.8 1.0 0.01, 0.22
PLA 4032 + KTP 59.1 0.57 81.5 20.7 160.7 39.5 18.8 0.18, 0.37
PLA 2002D + TCS/KTP 51.6 0.47 92.7 13.3 134.1 17.6 4.3 0.04, 0.17
PLA 4032D + TCS/KTP 52.6 0.45 109.8 5.0 149.5 23.6 18.6 0.17, 0.22
aData obtained from commercial pellet samples. bValues have been rescaled considering the theoretical content of TCS (i.e., 3% (w/v)) and KTP
(i.e., 1% (w/v)). cTemperature corresponding to the predominant melting peak. dDetermined by considering an estimated melting enthalpy of 106
J·g-1 for a 100% crystalline sample.39,40 Left and right values correspond to crystallinities deduced for the as electrospun material (i.e., consider-
ing ΔHm-ΔHc as the enthalpy associated to crystalline phase of the electrospun sample) and those attained after cold crystallization (i.e., consid-
ering ΔHm as the enthalpy associated to the final crystalline phase), respectively. 
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Figure 7. Release curves in PBS:EtOH medium of TCS ( □ ) and KTP (○ ) from single drug-loaded (a,c) and dual drug-loaded (b,d)
PLA 2002D (a,b) and PLA 4032D (c,d) electrospun scaffolds. 
Figure 6. Release curves in PBS medium of TCS (□) and KTP (○) from single drug-loaded (a,c) and dual drug-loaded (b,d) PLA 2002D
(a,b) and PLA 4032D (c,d) electrospun scaffolds. 
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of TCS and KTP from PLA 2002D scaffolds after 8 h of expo-
sure to PBS medium rose to 40% and 30%, respectively
(Figure 6(a)), while these percentages decreased to 30% and
5% for a similar exposure time when PLA 4032D scaffolds
were employed (Figure 6(c)). A similar trend was observed
in PBS:EtOH medium; specifically, the percentages of TCS
and KTP release from PLA 2002D scaffolds after 8 h of exposure
were, respectively, 80% and 60% (Figure 7(a)) and from PLA
4032D scaffolds, 50% and 30%, respectively (Figure 7(c)).
The influence of release medium and type of polymer
matrix on drug release was also observed when dual drug-
loaded scaffolds were evaluated (Figures 6(c), 6(d), 7(c), and
7(d)). An interesting observation about these dual systems is
that the release profiles for each drug were different from
those determined for single drug-loaded scaffolds. Specifi-
cally, a lower release percentage was always found in dual
scaffolds. Note that fiber diameters were smaller for these dual
systems, and consequently a contrary behavior should be
expected if release were only controlled by molecular diffu-
sion. Furthermore, drug release in dual systems seemed to
depend on the physicochemical characteristics of the amorphous
phase. Thus, decrease of the glass transition temperature or
suppression of the aging effect may favour the release. It should
be pointed out that crystallinity and molecular orientation were
too similar in single and dual scaffolds loaded with KTP to
justify the large differences found in the corresponding KTP
release profiles. Therefore, TCS and KTP molecules should
have some kind of intermolecular interactions inside micro-
fibers that change equilibrium distribution or hinder molec-
ular diffusion. 
Plots in Figures 6 and 7 also show that release evolves in a
gradual manner (i.e., without a significant burst effect indicative
of the presence of drugs deposited on the microfiber sur-
faces only) until a significant value is attained.
In addition to the maximum achievable release, it is also
interesting to compare the release rates, which can be easily
determined from the experimental results. Several theoreti-
cal models have been postulated to fit experimental release
profiles, typically first-order,41 Higuchi42 and their combina-
tion.43 Release generally occurs in two different steps, i.e., a
rapid release of molecules that should be deposited near on
the surface of fibers and a slow release that should involve
the diffusion of inner molecules through the polymer bulk
towards the release medium. In this way, a combined model
based on the Higuchi and first-order models (eqs. (1) and
(2)) is usually used to describe the first (0-60%) and second
(40-100%) parts of the release, respectively:
Mt / M0 = kHt (1⁄2)  (0  Mt / M0  0.6) (1)
ln(1-Mt  / M0) = a - k1t (0.4  Mt /M0  1.0) (2)
where kH is the Higuchi release constant, k1 is the first-order
release constant, Mt is the percentage of drug released at
time t, M0 is the drug equilibrium percentage (considered as
the maximum drug percentage) and a is a constant.
Table III summarizes the values of kH and k1 determined
for representative scaffolds and release media (i.e., those with a
significant release). Basically, the variations of k1 reflect ability
to reach the final equilibrium condition whereas kH values appear
more interesting because they quantify and allow comparing
drug release speed in the initial phase of delivery. This constant
Table III. Kinetic Constants for the First (0-60%) and Second Part (40-100%) of the TCS and KTP Release
Sample Drug Medium kH (h-0.5) k1 (h-1)
PLA 2002D + TCS TCS PBS:EtOH 0.78 0.58
PLA 4032D + TCS TCS PBS:EtOH 0.35 0.38
PLA 2002D + TCS/KTP TCS PBS:EtOH 0.78 0.97
PLA 4032D + TCS/KTP TCS PBS:EtOH 0.79 1.10
PLA 2002D + TCS TCS PBS 0.47 0.29
PLA 4032D + TCS TCS PBS 0.48 1.48
PLA 2002D + TCS/KTP TCS PBS 0.15 1.02
PLA 4032D + TCS/KTP TCS PBS 0.04 5.61
PLA 2002D + KTP KTP PBS:EtOH 0.50 0.39
PLA 4032D + KTP KTP PBS:EtOH 0.35 0.40
PLA 2002D + TCS/KTP KTP PBS:EtOH 0.25 1.60
PLA 4032D + TCS/KTP KTP PBS:EtOH 0.24 1.65
PLA 2002D + KTP KTP PBS 0.30 0.37
PLA 4032D + KTP KTP PBS 0.10 0.30
PLA 2002D + TCS/KTP KTP PBS 0.13 1.26
PLA 4032D + TCS/KTP KTP PBS 0.06 2.24
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is similar for TCS release in PBS:EtOH medium (0.78-0.79
h-0.5) from all scaffolds except from the single drug-loaded
PLA 4032D system, where a decrease was detected (0.35 h-0.5).
This constant clearly decreased (0.04-0.48 h-0.5) in PBS medium.
Release of KTP proceeded at a slower rate than TCS in both
media, with values of 0.24-0.50 h-0.5 and 0.06-0.30 h-0.5 for
PBS:EtOH and PBS media, respectively. The lower rates for
each range corresponded to scaffolds prepared from the more
regular PLA 4032D matrix. Finally, it is worth mentioning
that release of both KTP and TCS proceeded at a very slow
rate (0.06 and 0.04 h-0.5, respectively) when dual drug-loaded
systems and the more hydrophilic PBS medium were used.
Antibacterial Properties of TCS and KTP Loaded PLA
Scaffolds. Antibacterial activity of PLA 2002D and PLA
4032D electrospun scaffolds loaded with TCS and its com-
bination with KTP was tested against M. luteus and E. coli
bacteria (as representative of Gram-positive and Gram-neg-
ative bacteria, respectively). It is well known that TCS is a
broad-spectrum antiseptic with documented safety and effi-
cacy against both types of bacteria.44,45 Basically, TCS blocks
the active site of the enol-acyl carrier protein reductase enzyme,
which is essential in the synthesis of fatty acids in bacteria.46
Bacterial growth curves for E. coli and M. luteus are shown
in Figures 8(a) and (b), respectively. An initial lag phase
(4-5 h) followed by an exponential phase associated with
binary fission that stopped at growth levels clearly lower
than for the positive control is observed. Therefore, for both
types of bacteria, the results corroborate that single and dual
TCS-loaded scaffolds were active materials for inhibition of
bacterial growth. Bacterial growths between 5-10% and 10-
20% with respect to the positive control were observed for
E. coli and M. luteus, respectively, after 24 h of culture.
Curves were essentially independent of the polymer matrix,
and consequently antibacterial activity was not sensitive to
the differences found in the release experiments. It seems that
the high TCS content of scaffolds (i.e., 3% (w/v)) ensured a
sufficient release to inhibit bacterial growth even for matri-
ces with a fairly low release. It is also important to indicate
that the incorporation of KTP did not interfere with biological
activity of TCS, at least at the assayed concentrations, and
made possible the development of multifunctional materials
with antibacterial and anti-inflammatory activities.
Interestingly, an intermediate level of inhibition of bacterial
growth was also found for scaffolds only loaded with KTP,
demonstrating antibacterial activity. Non-steroidal anti-inflamma-
tory drugs (NSAID) are among the non-antibiotic drugs that
have antimicrobial effect. Sodium diclofenac is probably the
best NSAID archetype. Studies have demonstrated that this
dug exhibits a broad activity against Gram-positive and Gram-
negative bacteria for either in vitro or in vivo antimicrobial
assays. The antimicrobial mechanism may be attributed to
the inhibition of DNA synthesis in bacterial cells.47 In fact, KTP
is a NSAID that inhibits cyclooxygenase, leading to analge-
sic, anti-inflammatory and antipyretic properties but at the
same time it has some bactericide activity through a mecha-
nism that remains unclear.48 Figure 8 clearly shows that the
bactericide activity of KTP-loaded scaffolds depended on
the selected PLA matrix; specifically, the greatest activity
was observed for PLA 2002D. The result is in agreement with
the lower crystallinity found for this sample and the higher
release compared to the KTP-loaded PLA 4032D scaffold. 
Quantification of bacterial adhesion is another checkpoint
of bactericide activity. This activity is demonstrated for all
TCS-loaded scaffolds since the percentage of attached bac-
teria was always statistically lower than that of positive con-
trols, as shown in Figure 9. Nevertheless, activity was lower
against M. luteus because Gram-positive bacteria are less
sensitive to the effect of triclosan. Figure 9 also shows that
single KTP-loaded scaffolds were unable to inhibit bacterial
adhesion on their surface.
Cell Adhesion and Proliferation on Drug Loaded Scaf-
folds. Figures 10(a) and (b) show the behavior of two epithelial
cell lines (MDCK and Vero) in terms of cell adhesion and
proliferation on PLA electrospun scaffolds loaded with TCS
and/or KTP. In general, scaffolds allowed adhesion of epi-
thelial cells (Figure 10(a)), which is an important event for
restarting epithelialization of a damaged tissue. Nevertheless, a
Figure 8. Relative growth of Escherichia coli (a) and Micrococ-
cus luteus (b) on TCS (■ ,□ ), KTP (● ,○), and TCS/KTP (◆,◇)
loaded PLA electrospun scaffolds and polystyrene plate as pos-
tive control (▲). Full and empty symbols correspond to PLA
2002D and PLA 4032D samples, respectively. 
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low percentage of cells (18-36% with respect to the control)
adhered to the loaded PLA scaffolds. This highly significant
difference (p<0.001) was due to the large percentage of loaded
TCS (i.e., 3% (w/v)), which became cytotoxic to cells in culture.32
It is remarkable that a large percentage of adhesion was gener-
ally observed in dual drug-loaded scaffolds despite having
the same TCS content. Only the PLA 2002D scaffold showed
a slightly significant difference (borderline value with p<0.048).
Cytotoxicity can therefore be modulated by incorporating
KTP and even by modifying the PLA enantiomer composition.
These results are in clear agreement with the release experi-
ments, which indicated a decrease in the amount of delivered
TCS when KTP was also incorporated into the microfibers
and a higher release when the more amorphous PLA 2002D
was employed as a matrix. Finally, a large percentage of cell
adhesion was determined for PLA scaffolds loaded with the
anti-inflammatory KTP, similarly to the positive control.
Adhered cells kept their proliferative activity and ultimately
colonized the material, forming a monolayer tissue. Figure
10(b) quantifies cell growth, which was clearly related to the
previous cell adhesion event. Thus, the percentage of cells
growing on TCS-loaded PLA scaffolds was still lower than
for the positive control (i.e., 42-55%) but the difference was
statistically less significant (p<0.01) and relatively moderate.
Again, the dual drug-loaded scaffold did not show any statistical
difference with respect to the control, and therefore appears
to be an appropriate 3D matrix for cell growth.
Conclusions
Continuous electrospun microfibers of polylactide con-
taining antibacterial and anti-inflammatory agents (i.e., triclosan
and ketoprofen) can be successfully prepared using optimized
processing parameters and a mixture of chloroform, acetone
and dimethylsulfoxide as solvent. Thermal properties of electro-
spun microfibers were highly dependent on small variations
in the D-lactide content of PLA and the incorporation of small
ratios of TCS and/or KTP. Specifically, microfibers containing
KTP and prepared from the more regular PLA 4032D sam-
ple were crystalline as a result of the molecular orientation
induced by the electrospinning process and probably by the
nucleating effect of the incorporated drug.
Release of TCS and KTP from PLA electrospun scaffolds
depended on the hydrophilicity of the media, the stereoregu-
larity of the polymer matrix and the potential establishment
of intermolecular interactions in dual drug-loaded scaffolds.
Specifically, a decrease of the release percentage and the release
rate for both drugs was detected in the binary system. This feature
demonstrates the potential interest of the studied binary system
since the intrinsic cytotoxicity of TCS could be supressed
while the bactericide activity could be maintained. 
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